Cell-derived microparticles: A mediator of inflammation in aortic valve stenosis?

• References

• 1 Braunwald E. Aortic stenosis. Harrison’s Principles of Internal Medicine.. 16th Ed. New York, NY: McGraw Hill; 2005: 1396.
• 2 Rajamannan N, Otto CM. Targeted therapy to prevent progresion of calcified aortic stenosis. Circulation 2004; 110: 1180-1182.
• 3 Galant A. et al. C-reactiveprotein is increased in patients with degenerative aortic valve stenosis. J Am Coll Cardiol 2001; 38: 1078-1082.
• 4 Mazzone A. et al. Biological features (inflammation and neoangiogenesis) and atherosclerotic risk factors in carotid plaques and calcified aortic valve stenosis: teo different sites of the same disease?. Am J Clin Pathol 2006; 126: 494-502.
• 5 Diehl P. et al. Increased levels of circulating microparticles in patients with severe aortic valve stenosis. Thromb Haemost 2008; 99: 711-719.
• 6 Horstman LL. et al. Endothelial microparticles as markers of endothelial dysfunction. Frontiers in Bioscience 2004; 9: 1118-1135.
• 7 Miyazaki Y. et al. High shear stress can initate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996; 88: 3456-3464.
• 8 Nomura S. et al. High shear stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atheroscler 2001; 158: 277-287.
• 9 Pontiggia L. et al. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba. Thromb Haemost 2006; 96: 774-780.
• 10 Jy W. et al. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis 1995; 21: 217-231.
• 11 Barry OP. et al. Platelet microparticles enhance adhesive interactions between monocytes and endothelial cells. J Clin Invest 1997; 45: 271A.
• 12 Amirkhosravi A. et al. Platelet microparticles upregulate TF and VEGF in endothelial and melanoma cells in a CD40 ligand-dependent manner: Possible role in angiogenesis and metastasis. Blood 2002; 100: 63b.
• 13 Boulanger CM. et al. In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension 2007; 49: 902-908.
• 14 Jy W. et al. Interaction of endothelial microparticles (EMP) with leukocytes: potential roles of EMP in thrombosis and inflammation. Blood 2001; 98: 226a.
• 15 Sabatier F. et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002; 99: 3962-3970.
• 16 Jy W. et al. Endothelial microparticles (EMP) bind and activate monocytes: Elevated EMP-monocyte complexes in multiple sclerosis. Frontiers Biosci 2004; 9: 3137-3144.
• 17 Jimenez JJ. et al. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-beta 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult Scler 2005; 11: 310-315.
• 18 Brodsky SV. et al. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 2004; 286: H1910-H1915.
• 19 Van Wijk MJ. et al. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol 2002; 187: 1686-1693.
• 20 Boulanger CM. et al. Circulating microparticles from patients with myocardial infarctions cause endothelial dysfunction. Circulation 2001; 104: 2649-2652.
• 21 Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 161: 4382-4387.
• 22 Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor production in a JNK1 signalling pathway. J Biol Chem 1999; 274: 23111-23118.
• 23 Fukushima S. et al. A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1via retrograde intracoronary route. Circulation 2006; 114: 251-256.
• 24 Rychly J, Nebe B. Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction. Curr Pharm Des 2006; 12: 3799-3806.
• 25 Kieseir BC. et al. Treatment and treatment trials inmultiple sclerosis. Curr Opin Neurol 2007; 20: 286-293.
• 26 Nakamura K. et al. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12: 4628-4635.
• 27 Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis 2006; 36: 182-187.
• 28 O’Connell DJ. et al. Phosphatidylinositol 4,5-bisphosphate regulates activation-induced platelet microparticle formation. Biochem 2005; 44: 6361-6370.
• 29 Abid-Hussein MN. et al. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost 2007; 98: 1096-1107.
• 30 Liebe V. et al. Statin therapy of calcific aortic stenosis: hype or hope?. Eur Heart J 2006; 27: 773-778.
• 31 Cowell SJ. et al. A randomised trial of intensive lipid-lowering therapy in calcific aortic stenosis. New Engl J Med 2005; 352: 2389-2397.
• 32 Tramontano AF. et al. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Com 2004; 320: 34-38.
• 33 Tesselaar ME. et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 5: 520-527.
• 34 Tilley RE. et al. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res. 2008 epub Feb. 8, 2008.
• 35 Langer F. et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intracvascular coagulation. Ann Hematol. 2008 epub Feb. 22 2008
• 36 Bidot L. et al. Recurrent thrombosis is frequently associated with increased microparticle-mediated thrombin generation. Blood 2006; 108: 427a.
• 37 Horstman LL. et al. Cell-derived microparticles in ischemic cerebrovascular disorders. Int J Neurol. 2008 in press.
• 38 Moura LM. et al. New understanding about calcific aortic stenosis and opportunities for pharmacologic intervention. Curr Opin Cardiol 2007; 22: 572-577.
• 39 Helske S. et al. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 2007; 18: 483-491.